Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group Limited has called its annual general meeting for 5 June 2026 in Hong Kong, where shareholders will vote on adopting the audited financial statements for the year ended 31 December 2025 and approving a proposed final dividend of HK$0.169 per share. The agenda also includes the re-election of directors, re-appointment of HLB Hodgson Impey Cheng Limited as auditors, and granting the board a general mandate to issue up to 20% of the company’s existing share capital, which could enhance financial flexibility and support future capital-raising or strategic initiatives.
These resolutions, if passed, will maintain continuity in the company’s leadership and audit oversight while providing management with additional headroom to issue new shares outside of rights issues and employee schemes. For investors, the dividend proposal signals continued capital returns, whereas the expanded share issuance authority may create both opportunities for growth funding and potential dilution depending on how the mandate is exercised.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Bermuda-incorporated company listed on the Hong Kong Stock Exchange, operating in the pharmaceutical sector. The group focuses on developing, manufacturing and distributing pharmaceutical products, with its shares traded under stock code 00512 in the Hong Kong market.
Average Trading Volume: 5,600,779
Technical Sentiment Signal: Buy
Current Market Cap: HK$22.5B
For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.